(BVS) Bioventus - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 629m USD | Total Return: 38.1% in 12m
Avg Turnover: 4.51M
Qual. Beats: 1
Rev. Trend: 91.6%
Qual. Beats: 0
Warnings
Altman Z'' -0.87 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Idiosyncratic Leader
Bioventus Inc. (BVS) is a medical device company specializing in musculoskeletal therapies and pain management. The company develops and distributes a diverse portfolio of products, including hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, and ultrasonic surgical systems for bone resection and soft tissue ablation. Its restorative therapy segment focuses on minimally invasive fracture treatments and bone graft substitutes used in orthopedic and neurosurgical procedures.
Operating within the Health Care Equipment sector, Bioventus utilizes a direct-to-provider business model, selling specialized hardware and consumables to healthcare institutions and physicians. The orthopedic device market is characterized by high research and development costs and rigorous regulatory approval processes for new technologies. Further insights into the company’s financial health and valuation metrics are available on ValueRay.
Headquartered in Durham, North Carolina, Bioventus maintains an international footprint through a distribution network that serves both chronic pain management and surgical intervention markets. Key products like the Exogen ultrasound system and BoneScalpel target specific clinical needs in bone healing and precision tissue removal.
- Reimbursement rate changes for hyaluronic acid injections impact core revenue margins
- Expansion of peripheral nerve stimulation portfolio drives high-growth restorative therapy sales
- Integration of surgical and bone graft acquisitions affects debt leverage ratios
- Medicare coverage updates for ultrasonic bone healing systems influence domestic volume
- Global orthopedic procedure volume recovery dictates demand for surgical hardware products
| Net Income: 28.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 12.01 > 1.0 |
| NWC/Revenue: 17.65% < 20% (prev 13.14%; Δ 4.51% < -1%) |
| CFO/TA 0.16 > 3% & CFO 102.9m > Net Income 28.5m |
| Net Debt (256.4m) to EBITDA (107.7m): 2.38 < 3 |
| Current Ratio: 1.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.0m) vs 12m ago 6.06% < -2% |
| Gross Margin: 67.78% > 18% (prev 0.67%; Δ 6.71k% > 0.5%) |
| Asset Turnover: 85.89% > 50% (prev 82.11%; Δ 3.78% > 0%) |
| Interest Coverage Ratio: 2.63 > 6 (EBITDA TTM 107.7m / Interest Expense TTM 23.3m) |
| A: 0.16 (Total Current Assets 249.8m - Total Current Liabilities 148.1m) / Total Assets 650.5m |
| B: -0.51 (Retained Earnings -331.8m / Total Assets 650.5m) |
| C: 0.09 (EBIT TTM 61.3m / Avg Total Assets 671.0m) |
| D: -0.80 (Book Value of Equity -334.0m / Total Liabilities 416.3m) |
| Altman-Z'' = -0.87 = CCC |
| DSRI: 1.01 (Receivables 120.5m/118.1m, Revenue 576.3m/567.7m) |
| GMI: 0.99 (GM 67.78% / 67.17%) |
| AQI: 0.97 (AQ_t 0.58 / AQ_t-1 0.59) |
| SGI: 1.02 (Revenue 576.3m / 567.7m) |
| TATA: -0.11 (NI 28.5m - CFO 102.9m) / TA 650.5m) |
| Beneish M = -3.15 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 9.02 with a total of 706,335 shares traded.
Over the past week, the price has changed by -15.15%,
over one month by -9.89%,
over three months by +1.81% and
over the past year by +38.13%.
Bioventus has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy BVS.
- StrongBuy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.8 | 64.1% |
P/E Trailing = 22.6341
P/E Forward = 11.8203
P/S = 1.0909
P/B = 3.3282
P/EG = 1.1822
Revenue TTM = 576.3m USD
EBIT TTM = 61.3m USD
EBITDA TTM = 107.7m USD
Long Term Debt = 253.3m USD (from longTermDebt, last quarter)
Short Term Debt = 18.8m USD (from shortTermDebt, last quarter)
Debt = 292.3m USD (corrected: LT Debt 253.3m + ST Debt 18.8m) + Leases 20.2m
Net Debt = 256.4m USD (calculated: Debt 292.3m - CCE 35.8m)
Enterprise Value = 885.1m USD (628.7m + Debt 292.3m - CCE 35.8m)
Interest Coverage Ratio = 2.63 (Ebit TTM 61.3m / Interest Expense TTM 23.3m)
EV/FCF = 8.80x (Enterprise Value 885.1m / FCF TTM 100.6m)
FCF Yield = 11.37% (FCF TTM 100.6m / Enterprise Value 885.1m)
FCF Margin = 17.46% (FCF TTM 100.6m / Revenue TTM 576.3m)
Net Margin = 4.94% (Net Income TTM 28.5m / Revenue TTM 576.3m)
Gross Margin = 67.78% ((Revenue TTM 576.3m - Cost of Revenue TTM 185.7m) / Revenue TTM)
Gross Margin QoQ = 67.88% (prev 68.07%)
Tobins Q-Ratio = 1.36 (Enterprise Value 885.1m / Total Assets 650.5m)
Interest Expense / Debt = 7.97% (Interest Expense 23.3m / Debt 292.3m)
Taxrate = 12.64% (571k / 4.52m)
NOPAT = 53.6m (EBIT 61.3m * (1 - 12.64%))
Current Ratio = 1.69 (Total Current Assets 249.8m / Total Current Liabilities 148.1m)
Debt / Equity = 1.55 (Debt 292.3m / totalStockholderEquity, last quarter 188.9m)
Debt / EBITDA = 2.38 (Net Debt 256.4m / EBITDA 107.7m)
Debt / FCF = 2.55 (Net Debt 256.4m / FCF TTM 100.6m)
Total Stockholder Equity = 175.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 4.24% (Net Income 28.5m / Total Assets 650.5m)
RoE = 5.62% (Net Income TTM 28.5m / Total Stockholder Equity 506.9m)
RoCE = 8.07% (EBIT 61.3m / Capital Employed (Equity 506.9m + L.T.Debt 253.3m))
RoIC = 11.04% (NOPAT 53.6m / Invested Capital 485.3m)
WACC = 6.90% (E(628.7m)/V(921.0m) * Re(6.87%) + D(292.3m)/V(921.0m) * Rd(7.97%) * (1-Tc(0.13)))
Discount Rate = 6.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 4.79%
[DCF] Terminal Value 77.97% ; FCFF base≈69.9m ; Y1≈80.2m ; Y5≈118.0m
[DCF] Fair Price = 22.43 (EV 1.78b - Net Debt 256.4m = Equity 1.52b / Shares 67.7m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.27 | # QB: 1
Revenue Correlation: 91.55 | Revenue CAGR: 5.28% | SUE: 0.44 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.22 | Chg30d=-8.09% | Revisions=-33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.18 | Chg30d=-7.37% | Revisions=-20% | Analysts=5
EPS current Year (2026-12-31): EPS=0.78 | Chg30d=+3.47% | Revisions=+43% | GrowthEPS=+14.1% | GrowthRev=+6.6%
EPS next Year (2027-12-31): EPS=0.91 | Chg30d=+4.14% | Revisions=+50% | GrowthEPS=+16.8% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +50%